Calumet (CLMT) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
1 Dec, 2025Executive summary
Completed conversion from MLP to C-Corp in July 2024, increasing trading liquidity and strategic flexibility with over 99% unitholder approval.
Closed and funded DOE loan, with Montana Renewables receiving $782 million initial draw from $1.44 billion facility, reducing annual debt service by ~$80 million and supporting MaxSAF expansion.
Announced sale of Royal Purple industrial business for $110 million, with proceeds primarily for debt reduction and strategic alignment.
Achieved record specialty sales volumes and operational improvements, including cost reductions and de-risking at Montana Renewables.
Reported Q4 2024 net loss of $40.7 million and full-year net loss of $222.0 million; Q4 Adjusted EBITDA was $56.6 million, full-year Adjusted EBITDA $194.8 million.
Financial highlights
Q4 2024 Adjusted EBITDA was $56.6 million; full-year Adjusted EBITDA totaled $194.8 million.
Specialty Products and Solutions segment generated $43.4 million Adjusted EBITDA in Q4 and $193.6 million for the year.
Performance Brands segment posted $16.3 million in Q4 and $57.4 million for the year, with Q4 up 20% YoY.
Montana Renewables segment delivered $10.9 million Adjusted EBITDA in Q4 (up from $(25.8) million prior year) and $16.7 million for the year.
Q4 2024 sales were $949.5 million; full-year sales were $4,189.4 million, nearly flat year-over-year.
Outlook and guidance
DOE loan and Royal Purple sale proceeds to accelerate deleveraging and support Montana Renewables' MaxSAF expansion.
Montana Renewables free cash flow projected at $65 million–$85 million at $1.50/gal index margin, with upside from MaxSAF.
2025 capital spend projected at $60 million–$90 million, excluding MaxSAF expansion; MaxSAF expansion targeted to reach 150 million gallons in 2026 and 300 million gallons by 2028.
Restricted Group free cash flow expected at $95 million–$115 million annually, available for debt reduction.
Management prioritizes balance sheet deleveraging and cash flow growth, with expectations for continued operational momentum.
Latest events from Calumet
- Adjusted EBITDA rose 30%, net loss narrowed, and $222M debt was cut amid record specialty output.CLMT
Q4 202527 Feb 2026 - Q2 2024 delivered $66.8M EBITDA, record volumes, and C-Corp conversion amid margin pressure.CLMT
Q2 20241 Feb 2026 - Record SAF output, $1.44B DOE loan, and $150M sale-leaseback drive growth and liquidity.CLMT
Q3 202415 Jan 2026 - DOE loan enables major SAF expansion, debt reduction, and strategic growth for renewables.CLMT
Status Update10 Jan 2026 - Unitholders to vote on conversion to a corporation, exchanging units for shares and warrants.CLMT
Proxy Filing2 Dec 2025 - Q2 2025 posted a $147.9M loss, but cost cuts and specialty gains drove operational progress.CLMT
Q2 202523 Nov 2025 - Q1 2025 net loss deepened, but EBITDA, liquidity, and SAF expansion advanced.CLMT
Q1 202520 Nov 2025 - Q3 2025 saw record EBITDA, net income, and SAF progress, with cost cuts and deleveraging.CLMT
Q3 202513 Nov 2025